57522540232: Difference between revisions
From Verified Handles
American biotechnology company
57522540232
57522540232
(Created by auto-bot V1) |
(AB-V1) |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Exelixis}} | {{DISPLAYTITLE:Exelixis}} | ||
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.<small> from [https://en.wikipedia.org/wiki/Exelixis Wikipedia]</small> | Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.<small> from [https://en.wikipedia.org/wiki/Exelixis Wikipedia]</small> | ||
{{SF| | {{SF| | ||
{{Twt|exelixisinc}} | {{Twt|exelixisinc}} | ||
| Line 7: | Line 6: | ||
}} | }} | ||
{{IDF| | {{IDF| | ||
{{Isni|0000000404651644}} | {{Isni|0000000404651644}} | ||
}} | }} | ||
{{VHID|57522540232}}{{#subtitle: <big>American biotechnology company</big>}} | {{VHID|57522540232}}{{#subtitle: <big>American biotechnology company</big>}} | ||
Latest revision as of 19:18, 27 February 2022
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. from Wikipedia
| Icon | Service | Username | |
|---|---|---|---|
 |
@exelixisinc |  | |
 |
Website | exelixis.com | |
Additional identifiers
These are provided for reference and have been verified to be accurate.
| Icon | Database | Identifier | |
|---|---|---|---|
 |
ISNI | 0000000404651644 | |